NCT00813046已完成1 期
Preliminary Assessment of the Short Term Clinical Tolerability and Safety of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis
BioTech Tools S.A.2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2008年12月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- To demonstrate the clinical tolerability and safety of the treatment by looking at the absence of immediate allergic reaction.
研究概览
简要总结
The purpose of this study is to determine whether the oral administration of grass pollen peptides to treat allergic rhinitis is safe and well tolerated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 50 years
- •The subjects are in good physical and mental health according to his/her medical history, vital signs, and clinical status
- •Male or non-pregnant, non-lactating females
- •A history of seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen season during at least the last two years
- •A positive skin prick test to grass-pollen mixture
- •Specific IgE against grass pollen (RAST class 2 or IgE > 0.7 kU/l)
- •Asymptomatic to perennial inhalant allergens
排除标准
- •Subjects with current or past immunotherapy for SAR
- •Subjects requiring controller medication against asthma (bronchodilator nebulised drugs or local or systemic corticosteroids)
- •Documented evidence of acute or significant chronic sinusitis (as determined by individual investigator)
- •Subjects with a history of food allergy and consecutive anaphylaxis
- •Subjects with a history of hepatic or renal disease
- •Subject with malignant disease, autoimmune disease
- •Female subjects who are pregnant, lactating, or of child-bearing potential and not protected from pregnancy by a sufficiently reliable method (OCs, IUD).
- •Females unable to bear children must have documentation of such (i.e. tubal ligation, hysterectomy, or post menopausal [defined as a minimum of one year since the last menstrual period])
- •Any chronic disease, which may impair the subject's ability to participate in the trial (i.e. severe congestive heart failure, active gastric or duodenal ulcer, uncontrolled diabetes mellitus, etc...)
- •Subjects with clinically relevant abnormal QTc intervals of the ECG : QTc > 450 ms for man and > 470 ms for women
- •Subjects requiring beta-blockers medication
- •Chronic use of concomitant medications that would affect assessment of the effectiveness of the study medication (e.g. tricyclic antidepressants)
- •Subject with febrile illness (> 37.5°C, oral)
- •A known positive serology for HIV-1/2, HBs antigen or anti-HCV antibodies
- •The subject is immunocompromised by medication or illness, has received a vaccine, corticoids or immunosuppressive medications within 1 month before study entry
- •Receipt of blood or a blood derivative in the past 6 months preceding study entry
- •Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 4 weeks preceding the study, any consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 1 week preceding the study
- •Use of long-acting antihistamines
- •Any condition which could be incompatible with protocol understanding and compliance
- •Subjects who have forfeited their freedom by administrative or legal award or who are under guardianship,
- •Participation in another clinical trial and/or treatment with an experimental drug within 1 month of study start
- •A history of hypersensitivity to the excipients
结局指标
主要结局
To demonstrate the clinical tolerability and safety of the treatment by looking at the absence of immediate allergic reaction.
时间窗: 10 days
次要结局
- vital signs clinical laboratory evaluations adverse events general physical status(10 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic RhinoconjunctivitisSeasonal Allergic RhinoconjunctivitisNCT00833066BioTech Tools S.A.54
已完成
2 期
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic RhinoconjunctivitisGrass Pollen AllergyHay FeverNCT01308021BioTech Tools S.A.202
已完成
3 期
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in ChildrenAllergic RhinoconjunctivitisNCT00841256Allergopharma GmbH & Co. KG207
已完成
2 期
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance InductionGrass Pollen AllergyAllergic RhinoconjunctivitisNCT04502966National Institute of Allergy and Infectious Diseases (NIAID)199
Unknown
3 期
A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen RhinoconjunctivitisAllergic RhinoconjunctivitisNCT00812799Artu Biologicals374